<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602576</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000580808</org_study_id>
    <secondary_id>06604</secondary_id>
    <secondary_id>802514</secondary_id>
    <secondary_id>SPRI-UPCC-06604</secondary_id>
    <nct_id>NCT00602576</nct_id>
  </id_info>
  <brief_title>Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma</brief_title>
  <official_title>Randomized Phase II Study Comparing Two Schedules Of Temozolomide In Combination With Bay 43-9006 In Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth and by blocking blood flow to the tumor. Giving temozolomide together with sorafenib&#xD;
      may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying two different schedules of temozolomide&#xD;
      when given together with sorafenib to compare how well they work in treating patients with&#xD;
      metastatic or unresectable melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To measure the progression-free survival of patients with metastatic or unresectable&#xD;
           melanoma with no brain metastasis or no prior treatment with temozolomide (TMZ) treated&#xD;
           with sorafenib tosylate in combination with two different schedules (extended daily&#xD;
           dosing vs standard dosing) of TMZ.&#xD;
&#xD;
        -  To measure the progression-free survival of patients with or without brain metastasis&#xD;
           and prior treatment with TMZ treated with sorafenib in combination with extended daily&#xD;
           dosing of TMZ.&#xD;
&#xD;
        -  To measure the progression-free survival of patients with brain metastasis and no prior&#xD;
           treatment with TMZ treated with sorafenib in combination with standard dosing TMZ.&#xD;
&#xD;
        -  To estimate the median time to progression in all patients.&#xD;
&#xD;
        -  To quantify the number and percent of patients who have stable disease after 6 months of&#xD;
           treatment (failure to progress).&#xD;
&#xD;
        -  To choose the optimal combination dosing regimen for further study.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To estimate and define the objective response rate in these patients.&#xD;
&#xD;
        -  To characterize the duration of objective responses in these patients.&#xD;
&#xD;
        -  To estimate the incidence of new symptomatic brain metastasis in these patients.&#xD;
&#xD;
        -  To measure overall survival of these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to prior brain&#xD;
      metastases (yes vs no) and prior treatment with temozolomide (TMZ) (yes vs no). Patients with&#xD;
      no prior brain metastases who did not receive prior treatment with TMZ are randomized to 1 of&#xD;
      2 treatment arms. These patients are further stratified according to prior treatment with&#xD;
      sorafenib tosylate (yes vs no). Patients with or without prior brain metastases who received&#xD;
      prior treatment with TMZ are assigned to arm I. Patients with prior brain metastases who did&#xD;
      not receive prior treatment with TMZ are assigned to arm II.&#xD;
&#xD;
        -  Arm I: Patients receive oral sorafenib tosylate twice daily on days -7 to 56 of course 1&#xD;
           and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on&#xD;
           days 1-42.&#xD;
&#xD;
        -  Arm II: Patients receive sorafenib tosylate as in arm I and oral TMZ once daily on days&#xD;
           1-5 and 29-33.&#xD;
&#xD;
      In both arms, courses repeat every 8 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2005</start_date>
  <completion_date type="Actual">July 26, 2009</completion_date>
  <primary_completion_date type="Actual">December 21, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>4 arm parallel phase II study Arms A and B are randomized to different schedules of temozolomide Arm C is prior temozolomide-refractory patients Arm D is brain metastases patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed melanoma&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
          -  Measurable disease by RECIST criteria&#xD;
&#xD;
               -  Cutaneous lesions measuring at least 1 cm will be considered measurable disease&#xD;
&#xD;
          -  Brain metastases allowed provided patient completed radiotherapy, if radiotherapy was&#xD;
             clinically indicated at the time of diagnosis, AND discontinued steroids prior to&#xD;
             study enrollment&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  WBC ≥ 3,000/mm³&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times ULN (&lt; 3.0 times ULN if Gilbert's disease is present)&#xD;
&#xD;
          -  AST or ALT ≤ 2.5 times ULN (≤ 5.0 times ULN if liver metastases are present)&#xD;
&#xD;
          -  INR ≤ 1.5 (if on anticoagulation, baseline INR must be &lt; 1.5 before starting&#xD;
             anticoagulation)&#xD;
&#xD;
          -  PTT normal&#xD;
&#xD;
          -  No other concurrent malignancies, except basal cell or squamous cell skin cancer,&#xD;
             carcinoma in situ of the cervix, or ductal or lobular carcinoma in situ of the breast&#xD;
&#xD;
          -  No concurrent serious illness including, but not limited to, any of the following:&#xD;
&#xD;
               -  Ongoing or active infection requiring parenteral antibiotics&#xD;
&#xD;
               -  Clinically significant cardiovascular disease (e.g., uncontrolled hypertension,&#xD;
                  myocardial infarction, unstable angina)&#xD;
&#xD;
               -  New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
               -  Serious cardiac arrhythmia requiring medication&#xD;
&#xD;
               -  Peripheral vascular disease ≥ grade II within the past year&#xD;
&#xD;
               -  Psychiatric illness/social situation that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  Prior radiotherapy allowed&#xD;
&#xD;
               -  If radiotherapy has been administered to a lesion, there must be radiographic&#xD;
                  evidence of progression of that lesion for that lesion to constitute measurable&#xD;
                  disease or to be included in the measured target lesions&#xD;
&#xD;
          -  Prior temozolomide or sorafenib tosylate allowed&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior active immunotherapy (aldesleukin, interferon,&#xD;
             sargramostim [GM-CSF], or CTLA-4)&#xD;
&#xD;
          -  At least 4 weeks since prior and no other concurrent investigational anticancer&#xD;
             therapy (except vaccines)&#xD;
&#xD;
          -  No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin,&#xD;
             carbamazepine, or phenobarbital), rifampin, or Hypericum perforatum (St. John's wort)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Amaravadi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <disposition_first_submitted>April 16, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 16, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 22, 2020</disposition_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>August 24, 2020</submitted>
    <returned>September 10, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

